St. Luke's-Roosevelt Hospital Center
Trial Pipeline
Metabolically Healthy Obesity: Correlations Between BMI and Metabolic Syndrome Biomarkers
NCT03195712
Decision Making in End of Life as Individual Preferences
NCT02428504
Continuous Interscalene Block Results in Superior Recovery Throughout the First Postoperative Week
NCT01881776
Rapid Stress/Rest Single-Day Tc-99m Sestamibi Myocardial Single Photon Emission Computed Tomography
NCT01434641
Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo
NCT01401374
Effect of Meal Number, Frequency, and Form on Satiety and Metabolism After Weight Loss Surgery
NCT01938469
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
NCT01163552
Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children
NCT00857727
Evaluation of Syncope,Its Diagnosis, Treatment, Outcome and Prognosis
NCT00764985
Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo
NCT00334048
Abilify as an Adjunctive Treatment for Refractory Depression
NCT00220636
Pilot Study to Evaluate a Prototype Electronic Uterine Inhibitor to Prevent Preterm Contractions
NCT00212446
Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas
NCT00220649
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
What the Pipeline for St. Luke's-Roosevelt Hospital Center Shows
According to the ClinicalTrials.gov registry, St. Luke's-Roosevelt Hospital Center is linked to 13 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 13 are already marked complete, representing roughly 100% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for St. Luke's-Roosevelt Hospital Center reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 3 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for St. Luke's-Roosevelt Hospital Center is Obesity with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.